Merck Makes $50 Million Strategic Investment in Personalis to Advance Personalized Cancer Therapy

CACLPBooth No. 2025: 4-E0101

Personalis recently announced that it has signed multiple agreements with long-term partners Merck and Moderna to accelerate the advancement of its business strategy. As part of the agreements, Merck made a $50 million strategic investment in Personalis, while Moderna extended its multi-year collaboration agreement with Personalis to continue utilizing its ImmunoID NeXT Platform® to support the development of V940/mRNA-4157, an investigational personalized neoantigen therapy (INT) jointly developed by Merck and Moderna.

According to the agreement, Merck purchased common shares of Personalis through a private placement at a price of $3.56 per share, which was the closing price of Personalis stock on the Nasdaq Global Market on December 18, 2024. After the completion of the transaction, Merck will hold approximately 14 million shares of Personalis common stock, representing 16.5% of the company's total shares.

Personalis CEO Chris Hall stated, "Individualized therapies are redefining the future of cancer treatment. We are committed to supporting Merck and Moderna in advancing this transformative project, with the expectation of turning personalized oncology treatments into a standard care option for a broader population of cancer patients."

Since the launch of the V940/mRNA-4157 project, Personalis' ImmunoID NeXT Platform® has become a core tool in Merck and Moderna's oncology analysis efforts. "We value the long-term partnerships we have established with Merck and Moderna, and this investment further strengthens our strategic role in the field of precision oncology," Holle added.

① The final interpretation rights and copyrights of the original content published by this official account belong to ZhiAo RuiHe (Shanghai) Exhibition Co., Ltd. For reprinting, it is required to indicate the source as "CACLP In Vitro Diagnostics Information" at the beginning of the article, and please enter "reprint" in the information column to obtain reprint guidelines. ② Articles reprinted by this official account with a source are not representative of the views or positions of this platform. ③ Media cooperation: 021-52258212